SCYNEXIS to Participate in Upcoming Investor Conferences
SCYNEXIS (Nasdaq: SCYX), a clinical-stage biotechnology company, announced participation in two upcoming investor conferences in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SCYNEXIS (Nasdaq: SCYX), a clinical-stage biotechnology company, announced participation in two upcoming investor conferences in New York City. The company will join a fireside chat at the 12th Cantor Global Healthcare Conference on Friday, September 11, 2026, at 9:45 a.m. ET, which will be webcast live with a replay available for 90 days. SCYNEXIS will also take part in 1x1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference from September 14–16, 2026.
Details
News Market Reaction – SCYX
On Sep 1, the day this news came out, SCYX closed 1.15% below the previous close.
Data tracked by StockTitan Argus for the Sep 1 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced that the company will participate in the following investor conferences:
- 12th Cantor Global Healthcare Conference in New York City
Fireside chat: Friday, September 11, 2026, at 9:45 a.m. ET.
- H.C. Wainwright 28th Annual Global Investment Conference in New York City
1x1 investor meetings: September 14-16, 2026
A live webcast of the Cantor fireside chat will be available here. A replay will be available for 90 days following the event.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit www.scynexis.com
CONTACT:
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.